Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Total HBV / HDV Franchise by Quarter
Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M)
Gilead Sciences Total HBV / HDV Franchise: $259M in Q4 2023, up 1.6% from a year earlier. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2024-02-23) ↗
Reported in Form 10-Q / 10-K Disaggregated Revenue Note & Form 8-K Product Sales Summary.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total HBV / HDV Franchise (legacy sub-franchise breakout) ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 259 | +1.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2023 | Sep 30, 2023 | 269 | +1.9% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2023 | Jun 30, 2023 | 259 | +10.7% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2023 | Mar 31, 2023 | 230 | -2.1% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2022 | Dec 31, 2022 | 255 | -3.8% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2022 | Sep 30, 2022 | 264 | +6.9% | Form 10-Q (filed 2023-11-07) ↗ |
| Q2 2022 | Jun 30, 2022 | 234 | -1.3% | Form 10-Q (filed 2023-08-04) ↗ |
| Q1 2022 | Mar 31, 2022 | 235 | +6.8% | Form 10-Q (filed 2023-05-03) ↗ |
| Q4 2021 | Dec 31, 2021 | 265 | +8.6% | Form 10-K (filed 2024-02-23) ↗ |
| Q3 2021 | Sep 30, 2021 | 247 | +17.1% | Form 10-Q (filed 2022-11-02) ↗ |
| Q2 2021 | Jun 30, 2021 | 237 | +8.2% | Form 10-Q (filed 2022-08-08) ↗ |
| Q1 2021 | Mar 31, 2021 | 220 | +18.3% | Form 10-Q (filed 2022-05-04) ↗ |
| Q4 2020 | Dec 31, 2020 | 244 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 211 | – | Form 10-Q (filed 2021-11-03) ↗ |
| Q2 2020 | Jun 30, 2020 | 219 | – | Form 10-Q (filed 2021-08-05) ↗ |
| Q1 2020 | Mar 31, 2020 | 186 | – | Form 10-Q (filed 2021-05-06) ↗ |
Breakdown
What makes up total HBV / HDV Franchise
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — U.S. sales ($M)119 · Q4 2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Europe sales ($M)37 · Q4 2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Rest of World sales ($M)103 · Q4 2023
- Total HBV / HDV Franchise (legacy sub-franchise breakout) — Worldwide YoY growth (%)-4.0% · Q4 2022
- Viread (tenofovir disoproxil fumarate — legacy breakout) ($M)21 · Q4 2023
- Other HBV / HDV (Hepcludex / Hepsera — legacy breakout) ($M)21 · Q4 2023
Cite this data
StockData. (2026). Gilead Sciences Total HBV / HDV Franchise ($M), quarterly Q1 2020–Q4 2023 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/liver-hbv-hdv-total
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.